130 related articles for article (PubMed ID: 22161852)
1. Homologous recombination of wild-type JAK2, a novel early step in the development of myeloproliferative neoplasm.
Vilaine M; Olcaydu D; Harutyunyan A; Bergeman J; Tiab M; Ramée JF; Chen JM; Kralovics R; Hermouet S
Blood; 2011 Dec; 118(24):6468-70. PubMed ID: 22161852
[No Abstract] [Full Text] [Related]
2. Low frequency of JAK2 exon 12 mutations in classic and atypical CMPDs.
Ormazábal C; Hurtado C; Aranaz P; Erquiaga I; García-Delgado M; Calasanz MJ; Novo FJ; Vizmanos JL
Leuk Res; 2008 Sep; 32(9):1485-7. PubMed ID: 18291525
[No Abstract] [Full Text] [Related]
3. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
Baxter EJ; Scott LM; Campbell PJ; East C; Fourouclas N; Swanton S; Vassiliou GS; Bench AJ; Boyd EM; Curtin N; Scott MA; Erber WN; Green AR;
Lancet; 2005 Mar 19-25; 365(9464):1054-61. PubMed ID: 15781101
[TBL] [Abstract][Full Text] [Related]
4. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
[TBL] [Abstract][Full Text] [Related]
5. Concomitant JAK2 V617F-positive polycythemia vera and B-cell chronic lymphocytic leukemia in three patients originating from two separate hematopoietic stem cells.
Swierczek S; Nausova J; Jelinek J; Liu E; Roda P; Kucerova J; Jarosova M; Urbankova H; Indrak K; Prchal JT; Divoky V
Am J Hematol; 2013 Feb; 88(2):157-8. PubMed ID: 23280542
[TBL] [Abstract][Full Text] [Related]
6. The relationship of JAK2(V617F) and acquired UPD at chromosome 9p in polycythemia vera.
Wang L; Swierczek SI; Lanikova L; Kim SJ; Hickman K; Walker K; Wang K; Drummond J; Doddapaneni H; Reid JG; Muzny DM; Gibbs RA; Wheeler DA; Prchal JT
Leukemia; 2014 Apr; 28(4):938-41. PubMed ID: 24463469
[No Abstract] [Full Text] [Related]
7. The JAK2(V617F) tyrosine kinase mutation in blood donors with upper-limit haematocrit levels.
Tagariello G; Di Gaetano R; Sartori R; Zanotto D; Belvini D; Radossi P; Risato R; Roveroni G; Salviato R; Tassinari C; Toffano N
Blood Transfus; 2009 Apr; 7(2):111-6. PubMed ID: 19503632
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 overexpression correlates with JAK2-V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms.
Milosevic Feenstra JD; Jäger R; Schischlik F; Ivanov D; Eisenwort G; Rumi E; Schuster M; Gisslinger B; Machherndl-Spandl S; Bettelheim P; Krauth MT; Keil F; Bock C; Cazzola M; Gisslinger H; Kralovics R; Valent P
Am J Hematol; 2022 Apr; 97(4):390-400. PubMed ID: 35015307
[TBL] [Abstract][Full Text] [Related]
9. JAK2 mutations in polycythemia vera--molecular mechanisms and clinical applications.
Tefferi A
N Engl J Med; 2007 Feb; 356(5):444-5. PubMed ID: 17267904
[No Abstract] [Full Text] [Related]
10. After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera.
Grinfeld J; Godfrey AL
Blood Rev; 2017 May; 31(3):101-118. PubMed ID: 27884555
[TBL] [Abstract][Full Text] [Related]
11. Recent patents of gene mutation relative to JAK/STAT pathway and their implication in myeloproliferative diseases.
Shi Y; Xu C
Recent Pat DNA Gene Seq; 2008; 2(3):209-13. PubMed ID: 19075958
[TBL] [Abstract][Full Text] [Related]
12. Different expression patterns of LGALS1 and LGALS3 in polycythemia vera, essential thrombocythemia and primary myelofibrosis.
Moura LG; Tognon R; Nunes NS; Rodrigues LC; Ferreira AF; Kashima S; Covas DT; Santana M; Souto EX; Perobelli L; Simões BP; Dias-Baruffi M; Castro FA
J Clin Pathol; 2016 Oct; 69(10):926-9. PubMed ID: 27402956
[TBL] [Abstract][Full Text] [Related]
13. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
14. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.
Grand FH; Hidalgo-Curtis CE; Ernst T; Zoi K; Zoi C; McGuire C; Kreil S; Jones A; Score J; Metzgeroth G; Oscier D; Hall A; Brandts C; Serve H; Reiter A; Chase AJ; Cross NC
Blood; 2009 Jun; 113(24):6182-92. PubMed ID: 19387008
[TBL] [Abstract][Full Text] [Related]
15. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
16. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
[TBL] [Abstract][Full Text] [Related]
17. An increase in diagnostic JAK2 V617F mutation testing: Is masked polycythaemia vera the explanantion?
Langabeer SE
Eur J Intern Med; 2018 Jun; 52():e37-e38. PubMed ID: 29622375
[No Abstract] [Full Text] [Related]
18. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
19. Myeloproliferative neoplasms and JAK2 mutations.
Almedal H; Vorland M; Aarsand AK; Grønningsæter IS; Bruserud Ø; Reikvam H
Tidsskr Nor Laegeforen; 2016 Dec; 136(22):1889-1894. PubMed ID: 27929554
[TBL] [Abstract][Full Text] [Related]
20. Tissue factor activity is increased in neutrophils from JAK2 V617F-mutated essential thrombocythemia and polycythemia vera patients.
Reeves BN; Kim SJ; Song J; Wilson KJ; Henderson MW; Key NS; Pawlinski R; Prchal JT
Am J Hematol; 2022 Feb; 97(2):E37-E40. PubMed ID: 34748652
[No Abstract] [Full Text] [Related]
[Next] [New Search]
